A nanodroplet cell processing platform facilitating drug synergy evaluations for anti-cancer treatments

Ching Te Kuo, Jong Yueh Wang, Siang Rong Lu, Yu Sheng Lai, Hsiu Hao Chang, Jer-Tsong Hsieh, Andrew M. Wo, Ping-chi B Chen, Jen Her Lu, Hsinyu Lee

Research output: Contribution to journalArticle

Abstract

Therapeutic drug synergism intervened in cancer treatments has been demonstrated to be more effective than using a single effector. However, it remains inherently challenging, with a limited cell count from tumor samples, to achieve potent personalized drug cocktails. To address the issue above, we herein present a nanodroplet cell processing platform. The platform incorporates an automatic nanodroplet dispenser with cell array ParaStamp chips, which were fabricated by a new wax stamping approach derived from laser direct writing. Such approach enables not only the on-demand de-wetting with hydrophobic wax films on substrates but also the mask-less fabrication of non-planar microstructures (i.e. no photolithography process). The ParaStamp chip was pre-occupied with anti-cancer drugs and their associate mixtures, enabling for the spatially addressable screening of optimal drug combinations simultaneously. Each droplet with a critical volume of 200 nl containing with 100 cells was utilized. Results revealed that the optimal combination reduces approximate 28-folds of conducted doses compared with single drugs. Tumor inhibition with the optimally selected drug combination was further confirmed by using PC-3 tumor-bearing mouse models. Together, the nanodroplet cell processing platform could therefore offer new opportunities to power the personalized cancer medicine at early-stage drug screening and discovery.

Original languageEnglish (US)
Article number10120
JournalScientific Reports
Volume9
Issue number1
DOIs
StatePublished - Dec 1 2019

Fingerprint

Drug Evaluation
Neoplasms
Waxes
Drug Combinations
Drug Synergism
Therapeutics
Pharmaceutical Preparations
Precision Medicine
Preclinical Drug Evaluations
Drug Discovery
Masks
Lasers
Cell Count

ASJC Scopus subject areas

  • General

Cite this

A nanodroplet cell processing platform facilitating drug synergy evaluations for anti-cancer treatments. / Kuo, Ching Te; Wang, Jong Yueh; Lu, Siang Rong; Lai, Yu Sheng; Chang, Hsiu Hao; Hsieh, Jer-Tsong; Wo, Andrew M.; Chen, Ping-chi B; Lu, Jen Her; Lee, Hsinyu.

In: Scientific Reports, Vol. 9, No. 1, 10120, 01.12.2019.

Research output: Contribution to journalArticle

Kuo, Ching Te ; Wang, Jong Yueh ; Lu, Siang Rong ; Lai, Yu Sheng ; Chang, Hsiu Hao ; Hsieh, Jer-Tsong ; Wo, Andrew M. ; Chen, Ping-chi B ; Lu, Jen Her ; Lee, Hsinyu. / A nanodroplet cell processing platform facilitating drug synergy evaluations for anti-cancer treatments. In: Scientific Reports. 2019 ; Vol. 9, No. 1.
@article{7098b61723254d0ab2ebc56b86933e78,
title = "A nanodroplet cell processing platform facilitating drug synergy evaluations for anti-cancer treatments",
abstract = "Therapeutic drug synergism intervened in cancer treatments has been demonstrated to be more effective than using a single effector. However, it remains inherently challenging, with a limited cell count from tumor samples, to achieve potent personalized drug cocktails. To address the issue above, we herein present a nanodroplet cell processing platform. The platform incorporates an automatic nanodroplet dispenser with cell array ParaStamp chips, which were fabricated by a new wax stamping approach derived from laser direct writing. Such approach enables not only the on-demand de-wetting with hydrophobic wax films on substrates but also the mask-less fabrication of non-planar microstructures (i.e. no photolithography process). The ParaStamp chip was pre-occupied with anti-cancer drugs and their associate mixtures, enabling for the spatially addressable screening of optimal drug combinations simultaneously. Each droplet with a critical volume of 200 nl containing with 100 cells was utilized. Results revealed that the optimal combination reduces approximate 28-folds of conducted doses compared with single drugs. Tumor inhibition with the optimally selected drug combination was further confirmed by using PC-3 tumor-bearing mouse models. Together, the nanodroplet cell processing platform could therefore offer new opportunities to power the personalized cancer medicine at early-stage drug screening and discovery.",
author = "Kuo, {Ching Te} and Wang, {Jong Yueh} and Lu, {Siang Rong} and Lai, {Yu Sheng} and Chang, {Hsiu Hao} and Jer-Tsong Hsieh and Wo, {Andrew M.} and Chen, {Ping-chi B} and Lu, {Jen Her} and Hsinyu Lee",
year = "2019",
month = "12",
day = "1",
doi = "10.1038/s41598-019-46502-3",
language = "English (US)",
volume = "9",
journal = "Scientific Reports",
issn = "2045-2322",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - A nanodroplet cell processing platform facilitating drug synergy evaluations for anti-cancer treatments

AU - Kuo, Ching Te

AU - Wang, Jong Yueh

AU - Lu, Siang Rong

AU - Lai, Yu Sheng

AU - Chang, Hsiu Hao

AU - Hsieh, Jer-Tsong

AU - Wo, Andrew M.

AU - Chen, Ping-chi B

AU - Lu, Jen Her

AU - Lee, Hsinyu

PY - 2019/12/1

Y1 - 2019/12/1

N2 - Therapeutic drug synergism intervened in cancer treatments has been demonstrated to be more effective than using a single effector. However, it remains inherently challenging, with a limited cell count from tumor samples, to achieve potent personalized drug cocktails. To address the issue above, we herein present a nanodroplet cell processing platform. The platform incorporates an automatic nanodroplet dispenser with cell array ParaStamp chips, which were fabricated by a new wax stamping approach derived from laser direct writing. Such approach enables not only the on-demand de-wetting with hydrophobic wax films on substrates but also the mask-less fabrication of non-planar microstructures (i.e. no photolithography process). The ParaStamp chip was pre-occupied with anti-cancer drugs and their associate mixtures, enabling for the spatially addressable screening of optimal drug combinations simultaneously. Each droplet with a critical volume of 200 nl containing with 100 cells was utilized. Results revealed that the optimal combination reduces approximate 28-folds of conducted doses compared with single drugs. Tumor inhibition with the optimally selected drug combination was further confirmed by using PC-3 tumor-bearing mouse models. Together, the nanodroplet cell processing platform could therefore offer new opportunities to power the personalized cancer medicine at early-stage drug screening and discovery.

AB - Therapeutic drug synergism intervened in cancer treatments has been demonstrated to be more effective than using a single effector. However, it remains inherently challenging, with a limited cell count from tumor samples, to achieve potent personalized drug cocktails. To address the issue above, we herein present a nanodroplet cell processing platform. The platform incorporates an automatic nanodroplet dispenser with cell array ParaStamp chips, which were fabricated by a new wax stamping approach derived from laser direct writing. Such approach enables not only the on-demand de-wetting with hydrophobic wax films on substrates but also the mask-less fabrication of non-planar microstructures (i.e. no photolithography process). The ParaStamp chip was pre-occupied with anti-cancer drugs and their associate mixtures, enabling for the spatially addressable screening of optimal drug combinations simultaneously. Each droplet with a critical volume of 200 nl containing with 100 cells was utilized. Results revealed that the optimal combination reduces approximate 28-folds of conducted doses compared with single drugs. Tumor inhibition with the optimally selected drug combination was further confirmed by using PC-3 tumor-bearing mouse models. Together, the nanodroplet cell processing platform could therefore offer new opportunities to power the personalized cancer medicine at early-stage drug screening and discovery.

UR - http://www.scopus.com/inward/record.url?scp=85069005490&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85069005490&partnerID=8YFLogxK

U2 - 10.1038/s41598-019-46502-3

DO - 10.1038/s41598-019-46502-3

M3 - Article

C2 - 31300742

AN - SCOPUS:85069005490

VL - 9

JO - Scientific Reports

JF - Scientific Reports

SN - 2045-2322

IS - 1

M1 - 10120

ER -